Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AZN

2 of the Best Biotech Stocks to Buy This Month

The biotech industry is growing thanks to breakthrough advancements and government initiatives. Furthermore, during market downturns, the biotech sector is more defensive than others. So, fundamentally sound biotech stocks Pfizer (PFE) and AstraZeneca (AZN) could be worth buying. Read on.

StockNews.com

4 Best Pharma Stocks to Buy for the Long Haul

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy is likely to enter a recession, making pharma stocks attractive investment options. Therefore, investors could look to…

StockNews.com

3 Best Stocks to Buy Now for Long-Term Investors

Recent turmoil in the financial sector, renewed recession worries, and the Fed’s continued rate hikes paint an unfavorable picture for the stock market and economy. Amid this, long-term investors could opt for fundamentally sound stocks AstraZeneca (AZN), Cisco Systems (CSCO), and Ambev (ABEV) to withstand ongoing macroeconomic headwinds. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Don't Let These 2 Stocks Pass You by in 2023

With inflation remaining elevated, the Fed is expected to stay restrictive with its monetary policy. This is expected to keep the stock market volatile. Amid this backdrop, it could be wise for investors to buy fundamentally strong stocks AstraZeneca PLC (AZN) and General Motors Company (GM). Keep reading.

StockNews.com

The Best Stock to Buy for Under $100 Right Now

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

StockNews.com

2 Pharma Stocks to Buy Right Now and 1 You Might Want to Consider Selling

The pharmaceutical industry is evolving with personalized medicines and the rapid adoption of RPM technology, which should boost growth. Moreover, with a recession lurking, fundamentally strong pharma stocks AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) might be ideal buys. However, SNDL (SNDL) might be best avoided. Keep reading to know why.

StockNews.com

2 Large-Cap Stocks You Can Buy for Under $100

While rising inflation and the Fed’s rate hikes are expected to keep the stock market volatile in the near term, large-cap stocks could help survive. Therefore, fundamentally sound large-cap stocks, Coca-Cola (KO) and AstraZeneca (AZN), which are currently trading under $100, might be solid additions to your portfolio. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

1 Pharma Stock Poised for a Promising 2023

Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver solid returns this year. So, AZN could be an ideal buy. Keep reading.

StockNews.com

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

StockNews.com

Boost Your Portfolio With These Strong Buy Stocks

Expectations of the economy avoiding a recession have been rising amid the still-tight labor market and improving consumer sentiments. However, while uncertainties remain, quality stocks Walmart (WMT), AstraZeneca (AZN), and LSI Industries (LYTS), which are Strong Buy-rated in our proprietary system, could be ideal additions to boost your portfolios. Keep…

StockNews.com

3 Stocks to Help You Build Wealth in the Market

Receding inflationary pressure and the Fed’s smaller rate hike have raised investor optimism. However, amid additional rate hike fears and associated volatilities, investors could scoop up quality stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and AstraZeneca (AZN) that could help them build wealth in the market. Read on….

StockNews.com

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

StockNews.com

2 Pharma Stocks to Buy Now for Big Gains

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

StockNews.com

4 Pharma Stocks You Shouldn’t Think Twice About Buying in 2023

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Pharmaceutical Stocks You Can Always Rely On

The pharmaceutical industry is well-positioned to witness substantial growth, driven by the prevalence of chronic diseases, the aging population, and increased healthcare spending. Given the industry’s promising growth prospects, we think it could be wise to invest in fundamentally sound pharmaceutical stocks Johnson & Johnson (JNJ), Merck & Co (MRK),…

StockNews.com

5 Amazing Stocks You Won’t Ever Regret Buying

Easing inflation and the Fed’s indication of slowing the pace of interest rate hikes are raising investors’ sentiments. Moreover, the November job report came in better than expected. While uncertainties remain, we think quality stocks Pfizer (PFE), AstraZeneca PLC (AZN), Carrier Global (CARR), J. Jill (JILL), and Lifeway Foods (LWAY)…

StockNews.com

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

Benzinga

This Is What Whales Are Betting On AstraZeneca

Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine

Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the…

Benzinga

AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study

AstraZeneca Plc (NASDAQ:AZN) announced high-level results from a planned interim analysis of the AEGEAN Phase 3 trial of Imfinzi (durvalumab) combined with neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The data showed that Imfinzi plus neoadjuvant chemo before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete…

Benzinga

AstraZeneca Whale Trades For June 29

Benzinga

What Are Whales Doing With AstraZeneca

Benzinga

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised. The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of…

Benzinga

Short Volatility Alert: AstraZeneca PLC

On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall sentiment for AZN has been Bullish.

Benzinga

AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

1 2 3 4 5

People

Sristi Suman Jayaswal

90 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.